[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638439":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":24,"locations":34,"responsibleParty":52,"collaborators":23,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":23,"enrollmentInfo":64,"targetDuration":23,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":37,"whyStopped":23,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Institut Paoli-Calmettes","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"patients with localized NSCLC","This project is based on the prospective collection of blood and tumor samples from NSCLC patients, along with the corresponding clinical data.One hundred patients with localized NSCLC will be enrolled at each participating center; these are patients with resectable NSCLC treated by surgery.",[12],"Procedure: prospective collection of blood and tumor samples",{"label":14,"type":6,"description":15,"interventionNames":16},"patients with advanced NSCLC","One hundred patients with advanced NSCLC will be enrolled at the center whose Principal Investigator is the scientific coordinator. These are patients with unresectable NSCLC who are not eligible for surgery and whose initial treatment consists of medical therapy (chemotherapy and\u002For immunotherapy). The samples are obtained using non-invasive techniques (mostly CT-guided biopsy and, less frequently, bronchoscopic or esophageal endoscopic biopsy).",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","prospective collection of blood and tumor samples","The procedure under study is based on the collection of tissue and blood samples at two time points during the patient's management. The patient will undergo a first sampling at the time of inclusion in the study, followed by a second sampling performed at the time of disease progression. Two types of samples will be collected: blood samples and tumor samples.\n\nThe protocol-mandated tumor sampling at progression will be performed in the following two situations:\n\n1. If, as part of routine clinical care, a biopsy is planned, an additional tumor sample for the study will be collected.\n2. If the patient has consented to undergoing a protocol-specific tumor biopsy at the time of progression",[14,9],null,[25,30],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},"Jihane pakradouni","CONTACT","0491223824","pakradounij@ipc.unicancer.fr",{"name":31,"role":27,"phone":32,"phoneExt":23,"email":33},"allison arthur","0491223448","arthura@ipc.unicancer.fr",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Rochigneux","RECRUITING","Marseille","Institut Paoli Calmettes","13009","France","FR",{"type":44,"coordinates":45},"Point",[46,47],5.38107,43.29695,{"lat":47,"lon":46},[50],{"name":51,"role":27,"phone":32,"phoneExt":23,"email":23},"allison ARTHUR",{"type":53,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100638439","immuno-lung--identification-of-biomarkers-and-therapeutic-targets-for-pulmonary-immunotherapy-100638439",false,"NCT07608835","IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy","IMMUNO-LUNG: Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy - IMMUNOLUNG-IPC 2021-069","IMMUNOLUNG","Inclusion Criteria:\n\n* Patients aged 18 years or older, male or female.\n* Willing to participate in the study and having signed a written informed consent form.\n* Presenting a strong suspicion of localized resectable or advanced unresectable non-small cell lung cancer, or having a histologically confirmed non-small cell lung cancer.\n* Affiliated with a social security system or benefiting from such a system.\n\nExclusion Criteria:\n\n* Individuals in an emergency situation, adults under legal protection (guardianship, curatorship, or judicial protection), or individuals unable to provide informed consent.\n* Inability to comply with the medical follow-up required by the study for geographical, social, or psychological reasons.\n* History of solid organ transplantation or hematopoietic stem cell transplantation.\n* Pregnant or breastfeeding women.","ALL","18 Years",{"count":65,"type":66},200,"ESTIMATED","INTERVENTIONAL",[69],"NA","Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents. This research aims to identify biomarkers of response to immunotherapy at the tumor level and to characterize new therapeutic targets",[72],"Non-small Cell Lung Cancer",[74,75,76],"lung cancer","immunotherapie","progression free survival","2026-05-19",{"date":79,"type":80},"2026-05-27","ACTUAL",{"date":82,"type":80},"2026-02-12",{"date":84,"type":66},"2033-05-12",{"name":5,"class":6},1]